Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise ...
The deal will allow Novavax to lift its "going concern" warning, which it first issued in 2023 due to having "substantial ...
Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will receive $500 million in ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi (SNY, FR:SAN). Novavax shares were up 133% in recent trading at $10.11.
, opens new tab on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi (SASY.PA) , opens new tab for its COVID-19 vaccine in exchange for a stake that valued the U.S ...
Vaccine Maker Also Reported Q1 Earnings That Missed Estimates Friday Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the ...
(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Most Read from ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
Novavax (NASDAQ:NVAX) on Friday said it has signed a multi-billion-dollar deal with French drugmaker Sanofi (NASDAQ:SNY) to co-commercialize the company's Covid vaccine starting next year and ...